Cann P A, Read N W, Holdsworth C D
Gut. 1983 Dec;24(12):1135-40. doi: 10.1136/gut.24.12.1135.
Symptom scores, stool data, and the transit of a standard, solid meal were measured in 25 patients with irritable bowel syndrome during baseline conditions and after four weeks treatment with placebo and domperidone in the form of a double-blind cross-over trial. All patients had previously undergone a comprehensive series of diagnostic investigations and had failed to respond to dietary supplementation with coarse wheat bran (10-30 g daily). Compared with placebo treatment, domperidone had no significant effect on gastric emptying, small bowel or whole gut transit times, stool weight, frequency, or consistency. Most symptoms improved significantly with both placebo and domperidone treatments, compared with the baseline period, but there was no significant difference between placebo and domperidone for any of the symptoms. Abdominal distension, however, was reported on more days per week during domperidone treatment (p = 0.02). The findings in this study do not support the use of domperidone in the management of irritable bowel syndrome.
在一项双盲交叉试验中，对25例肠易激综合征患者在基线状态以及接受四周安慰剂和多潘立酮治疗后，测量了症状评分、粪便数据以及标准固体餐的通过情况。所有患者此前均接受了一系列全面的诊断检查，且对每日补充10 - 30克粗麦麸的饮食疗法无反应。与安慰剂治疗相比，多潘立酮对胃排空、小肠或全肠道通过时间、粪便重量、频率或稠度均无显著影响。与基线期相比，安慰剂和多潘立酮治疗后大多数症状均有显著改善，但安慰剂和多潘立酮在任何症状方面均无显著差异。然而，在多潘立酮治疗期间，每周报告腹胀的天数更多（p = 0.02）。本研究结果不支持使用多潘立酮治疗肠易激综合征。
